# TransCode (RNAZ) — News

RNAZ · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/rnaz/news

## Recent headlines

- [Natera & Transcode Therapeutics collaborate on CRC](https://www.ainvest.com/news/natera-transcode-therapeutics-collaborate-crc-2610) — AInvest Wire, Oct 13, 2026
  Natera, Inc. (NASDAQ: NTRA) has announced a collaboration with Transcode Therapeutics to advance research and development in the detection and treatment of colorectal cancer (CRC). The partnership aims to leverage Natera’s expertise in genomic analysis and Transcode’s innovative therapeutic…
- [Natera and Transcode Therapeutics to collaborate on phase 2A trial of TTX-MC138 in colorectal cancer](https://www.ainvest.com/news/natera-transcode-therapeutics-collaborate-phase-2a-trial-ttx-mc138-colorectal-cancer-2610) — AInvest Wire, Oct 13, 2026
  Natera, Inc. (NASDAQ: NTRA) and Transcode Therapeutics have announced a collaboration to conduct a phase 2A clinical trial of TTX-MC138, an investigational therapy targeting colorectal cancer. The trial aims to evaluate the safety, tolerability, and preliminary efficacy of TTX-MC138 in patients…
- [Transcode Therapeutics - Three patients remain progression-free at one year](https://www.ainvest.com/news/transcode-therapeutics-patients-remain-progression-free-year-2609) — AInvest Wire, Sep 28, 2026
  TransCode Therapeutics, Inc. (NASDAQ: TCDT) has reported that three patients treated with its lead therapeutic candidate, TTX-MC138, remain progression-free at one year. This update comes as the company continues to advance its clinical development programs in oncology. TTX-MC138 is an…
- [Transcode Therapeutics - Primary endpoint of phase 1A study met](https://www.ainvest.com/news/transcode-therapeutics-primary-endpoint-phase-1a-study-met-2609) — AInvest Wire, Sep 28, 2026
- [Transcode reports continued disease stabilization and extended treatment duration with TTX-MC138 in ongoing phase 1A clinical trial follow-up](https://www.ainvest.com/news/transcode-reports-continued-disease-stabilization-extended-treatment-duration-ttx-mc138-ongoing-phase-1a-clinical-trial-follow-2609) — AInvest Wire, Sep 28, 2026

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).